Key points are not available for this paper at this time.
Abstract Gastric intestinal metaplasia (GIM) is a precursor lesion for the intestinal subtype of gastric cancer (GC). A risk stratification tool is the Operative Link on GIM (OLGIM), a system that relies on histopathologic annotation of gastric biopsies. Advanced OLGIM (stages III and IV) have the highest risk of progression to GC. Molecular biomarkers for advanced OLGIM are lacking. We explored transcriptomics biomarkers for advanced OLGIM to aid risk assessment efforts among GC precursors. We used clinical and genomic data from four cohorts: 1) GAPS, a cohort of OLGIM-staged patients (N=303) ; 2) a subset of confirmed intestinal-type GC from The Cancer Genome Atlas (TCGA, N=198) ; 3) a compilation of scRNA-seq data (N=40), and 4) a spatial transcriptomics cohort (N=5) with annotated H Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 1140.
Wichmann et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: